BMS goes deeper with Owkin for data-driven clinical trial design

Building on their existing collaboration, BMS and Owkin are launching a multiyear partnership for data-driven trial design, with an initial focus on cardiovascular diseases.

Owkin Inc. will receive a total of $80 million in upfront payment and series B-1 equity investment from  Bristol Myers Squibb Co. (NYSE:BMY), and is eligible for more than $100 million in regulatory milestones...